3,52,4-dihydroxyacetophenone | 86936-86-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,52,4-dihydroxyacetophenone
• 英文别名: 1-[3,5-di(2H-1,2,3-benzotriazol-2-yl)-2,4-dihydroxyphenyl]ethan-1-one；3,5-[di(2H-benzotriazole-2-yl)]-2,4-dihydroxyacetophenone；1-[3,5-Bis(benzotriazol-2-yl)-2,4-dihydroxyphenyl]ethanone
• CAS: 86936-86-9
• 化学式: C₂₀H₁₄N₆O₃
• 分子量: 386.37
• InChiKey: NYMOLOKTUDWTBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-硝基苯重氮氯化物 、 2,4-二羟基苯乙酮 生成 3,52,4-dihydroxyacetophenone
  参考文献：
  名称：

  VOGL, OTTO;LI, SHANJUN

  摘要：

  DOI：

文献信息

• Funktionelle Polymere, 40. Mitt.: Synthese von mono- und di(4-methoxy)benzotriazol-substituierten 2,4-Dihydroxyaceto(oder benzo)phenonen
  作者：Shoukuan Fu、Shanjun Li、Otto Vogl

  DOI：10.1007/bf00810072

  日期：——
• VOGL, OTTO;LI, SHANJUN
  作者：VOGL, OTTO、LI, SHANJUN

  DOI：——

  日期：——
• NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
  申请人：Council of Scientific & Industrial Research

  公开号：EP2552444A1

  公开（公告）日：2013-02-06
• US9335332B2
  申请人：——

  公开号：US9335332B2

  公开（公告）日：2016-05-10
• [EN] NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY<br/>[FR] INHIBITEUR DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NMPRTASE) POUR LA THÉRAPIE DE GLIOMES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2011121434A1

  公开（公告）日：2011-10-06

  The present invention relates to identification of a compound which inhibits the enzyme NMPRTase and glioma cancer cell growth and further used for glioma therapy. Pre-B- cell colony enhancing factor 1 gene (PBEF1) encodes nicotinamide phosphoribosyltransferase (NMPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. PBEF1 transcript and protein levels have been shown to be elevated in glioblastoma and a chemical inhibitor of NMPRTase has been shown to specifically inhibit cancer cells. Here a structure based drug discovery approach has been reported with an aim to develop novel inhibitors for glioblastoma therapy. Present invention relates to virtual screening using docking of ligands from a large library of 13,000 compounds against NMPRTase as the macromolecular target resulting in short listing of 34 possible ligands, of which six were tested experimentally, using the NMPRTase enzyme inhibition assay and further with the glioma cell viability assays. Of these, two compounds were found to be significantly efficacious in inhibiting the conversion of nicotinamide to NAD, and out of which one compound, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl-)-l,2- dihydroisoquinolin-l -one, was found to inhibit the growth of a PBEF1 over expressing glioma derived cell line U87 also.